NICE approval for Janssen’s Darzalex combination
Recommendation concerns routine use across the NHS as therapy for multiple myeloma
Read Moreby John Pinching | Apr 26, 2023 | News | 0
Recommendation concerns routine use across the NHS as therapy for multiple myeloma
Read Moreby Lucy Parsons | Aug 27, 2021 | News | 0
Draft guidance shows concerns on cost-effectiveness of treatment
Read Moreby Lucy Parsons | Jan 19, 2021 | News | 0
Darzalex, Rozlytrek and Tavlesse among newly accepted drugs
Read Moreby Selina McKee | Aug 21, 2020 | News | 0
The approval broadens the drug’s label to include fifth treatment option in the relapsed/refractory multiple myeloma setting
Read Moreby Lucy Parsons | Aug 3, 2020 | News | 0
Subcutaneous formulation of Darzalex in combination with pomalidomide and dexamethasone meets primary endpoint
Read Moreby Anna Smith | Jan 22, 2020 | News | 0
The approval was based on results from part one of the Phase III CASSIOPEIA study.
Read Moreby Selina McKee | Dec 11, 2019 | News | 0
The drug has hit survival and disease progression targets in Phase III trials
Read Moreby Anna Smith | Jul 9, 2019 | News | 0
The Scottish Medicines Consortium (SMC) has announced its latest round of decisions for NHS Scotland, publishing advice accepting three new medicines.
Read Moreby Anna Smith | Jun 28, 2019 | News | 0
Dupixent is the first and only biologic treatment for adults with chronic rhinosinusitis with nasal polyposis.
Read Moreby Anna Smith | Jun 3, 2019 | News | 0
The drug showed non-inferior efficacy and a significantly higher complete response rate in two different trials.
Read Moreby Selina McKee | Mar 12, 2019 | News | 0
Myeloma patients in England are set to gain NHS access to a new second-line treatment combination following a first relapse of the disease.
Read Moreby Selina McKee | Dec 4, 2018 | News | 0
Janssen has unveiled data from a late-stage trial backing earlier use of its first-in-class biologic daratumumab (marketed as Darzalex) in patients with mutiple myeloma.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
